News

At Biogen Diagnóstica, we are committed to technologies that deliver greater safety, efficiency and quality of care for healthcare professionals and patients. In this context, we are sharing the key conclusions from the presentation by Dr María del Monte Trujillo Pérez, leading haematologist and Director of the Jaén Centre for Transfusion, Tissues and Cells, on the system developed by Meise Medizintechnik GmbH, designed for the production and preparation of serum eye drops.

Safety and purity through a closed system

One of the key advantages of the MEISE system is its comprehensive closed-system process, which prevents blood from coming into contact with ambient air throughout preparation. This procedure significantly reduces the risk of contamination and ensures a final product with the highest levels of purity and biological safety.

The use of advanced closed-system technology represents an important step forward for hospitals and laboratories seeking to optimise the preparation of serum eye drops under more demanding quality standards.

Guaranteed sterility for patients

The system incorporates a 0.22-micron filter, designed to ensure the final sterility of the product. According to Dr Trujillo, this technology preserves the integrity of the serum’s beneficial components, giving patients the reassurance of receiving treatment prepared to advanced quality and safety standards.

Thanks to this controlled process, the MEISE system helps improve reliability and traceability in the production of sterile serum eye drops, a key aspect of advanced ophthalmology.

From an artisanal process to a semi-automated solution

MEISE enables a transition from manual methods to a semi-automated model, optimising time and increasing production capacity. This results in greater hospital efficiency, the ability to treat more patients and improved safety for healthcare professionals by reducing exposure to aerosols and splashes.

Partial automation also makes it easier to standardise product preparation, reducing variability and improving the final quality of treatment.

Autologous and homologous serum: the same safety, different indications

Dr María del Monte Trujillo highlights that autologous serum remains the first choice because of its complete biocompatibility: “the patient is their own medicine”. However, homologous serum is essential when repeated blood draws are not possible or clinical conditions prevent them.

In both cases, the MEISE system ensures the same standards of filtration, sterility and quality, providing a safe environment for preparing personalised ophthalmic treatments.

Technology serving advanced ophthalmology

The introduction of solutions such as MEISE, distributed in Spain by Biogen Diagnóstica, represents a significant advance in the production of serum eye drops. It offers hospitals and specialised centres a safer, more efficient tool aligned with the needs of modern medicine.

At Biogen Diagnóstica, we remain committed to bringing high-value healthcare innovation and technology closer to health professionals, promoting solutions that improve both clinical processes and patient safety.

More information about the MEISE system

Extracorporeal membrane oxygenation (ECMO) support has become established in recent years as one of the most advanced therapies for the treatment of critically ill patients with severe respiratory or cardiac failure. However, its growing implementation across hospitals in Spain is creating new organisational challenges for the healthcare system.

This was one of the central themes discussed during the 1st ECMO Update Conference in Spain. Held on 26 February at the Ramón y Cajal University Hospital in Madrid and organised by the Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC), the event brought together national and international specialists to analyse the current situation of extracorporeal support in Spain and to share clinical, organisational and training experiences.

A highly complex therapy on the rise

ECMO is an extracorporeal life support technique that temporarily replaces the function of the heart and/or lungs through an external circuit that oxygenates the blood and returns it to the body. It is used in critical situations such as severe respiratory failure, cardiogenic shock or refractory cardiac arrest, when conventional treatments are no longer sufficient.

In Spain, the development of specialised intensive care medicine programmes focused on ECMO has progressed significantly. This growth, led by multidisciplinary teams, has made it possible to expand clinical indications and dramatically improve the care provided to critically ill patients.

The current challenge: organising the healthcare system

During the conference, several specialists highlighted that the expansion of ECMO programmes has not always been accompanied by coordinated regional planning. According to the experts, the current organisation varies between Spain’s autonomous communities, creating differences in coverage, coordination between centres and critical care patient transport models.

In response to this situation, professionals from SEMICYUC stressed the need to move towards a structured national strategy for adult ECMO support, with the aim of ensuring:

• Equal access to therapy throughout the country.
• Consistency in healthcare quality standards.
• Sustainability of the public healthcare system.

International models show that the creation of reference centres, clearly defined referral networks and specialised transport systems helps to improve patient safety and the efficiency of clinical outcomes.

Training, research and care coordination

Another key topic discussed was the importance of strengthening national registries, outcome auditing and specialised ECMO training programmes. Collaboration between hospitals, scientific societies and healthcare authorities is considered essential for consolidating this advanced therapy.

Spain has highly qualified professionals in intensive care. The current challenge lies in improving organisational coordination in order to guarantee equal access and maintain high standards of quality in the management of critically ill patients.

Source: Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC)

Spain has once again reaffirmed its position as a global leader in organ transplantation, surpassing 6,300 procedures carried out in 2025, with a rate of 51.9 donors per million population. These figures consolidate the Spanish healthcare model and its firm commitment to organ donation and transplantation.
>According to data presented by the National Transplant Organisation (ONT), 6,335 organ transplants were performed in 2025, keeping Spain at the top internationally for the second consecutive year in a medical activity of high complexity and enormous social impact.

Technological innovation and advanced organ preservation

One of the key factors behind this leadership is the adoption and widespread use of organ preservation procedures using extracorporeal circulation devices (ECMO). This advanced technology makes it possible to maintain the viability of organs suitable for transplantation. Even in highly complex clinical situations, leading to improved clinical outcomes and expanding therapeutic options for patients.

Cardiac transplantation after circulatory death: a clinical milestone

Due to its particular technical complexity, only nine countries worldwide successfully carry out this type of procedure. In Spain, cardiac transplantation after circulatory death, performed following the donor’s cardiorespiratory arrest, now accounts for 35% of all heart transplants. This figure reflects the high level of clinical and technological development of the Spanish transplant system.

A strong and coordinated healthcare system

In addition to heart transplantation, kidney, liver, lung and other specialised transplants have contributed to maintaining exceptional donation and transplantation figures. All of this is the result of a robust, well-coordinated healthcare system with a long-standing record of excellence in this field.

Organisational model, solidarity and innovation

The combination of an efficient organisational model, a strong culture of solidarity and technological advances such as ECMO systems has enabled Spain not only to maintain. Also to continue strengthening its global leadership in organ transplantation, setting the benchmark for advanced medicine and healthcare innovation.

The upcoming 12 and 13 November 2025, the Hospital La Fe de Valencia will host one of the most outstanding events of the year in the field of interventional cardiology, Tacit Meeting 2025, and Biogen Diagnóstica will participate as one of the 12 official sponsors.

This event will bring together interventional cardiologists from around the world to share experiences, knowledge, and the latest innovations in structural heart interventions. With 7 international speakers, 6 live clinical cases over 2 days of intensive practical training, the event aims to provide an advanced learning tool for professionals already experienced in structural therapies.

At Biogen Diagnóstica, we believe that innovation and specialised training are essential to advancing cardiovascular healthcare. Supporting initiatives like this reflects our commitment to medical progress, clinical excellence, and continuous improvement in interventional cardiology procedures.